Brief: European Medicines Agency Grants Orphan Drug Designation For MT-401 Developed By Marker Therapeutics For Treatment Of AML Patients
10/07/2023 12:41
July 10 (Reuters) - Marker Therapeutics Inc MRKR.O :
* EUROPEAN MEDICINES AGENCY GRANTS ORPHAN DRUG DESIGNATION
FOR
MT-401 DEVELOPED BY MARKER THERAPEUTICS FOR THE TREATMENT OF AML
PATIENTS
Source text for Eikon: ID:nGNX4YLCF1
Further company coverage: MRKR.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Marker Therapeutics
See all newsBrief: Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant To Advance MT-601 In Pancreatic Cancer
Marker Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Marker Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
Marker Therapeutics 2025 net loss widens, hurt by decline in grant income
Brief: Marker Therapeutics FY Basic EPS USD -0.79